Researchers at the University of Miami Miller School of Medicine have found a biomarker-fibroblast growth factor 23-that
could help predict whether a patient with early stages of kidney disease is at
risk of progressing to and dying from end-stage renal disease.1 The
team thinks the ability to pick out such patients could allow earlier
intervention and could improve prognosis, but other researchers are not yet
convinced the new biomarker offers such benefits.
Researchers were split on whether early
knowledge of a patient's likelihood of progressing to ESRD will significantly
change treatment decisions.
Martz, L. SciBX
Published online July 21, 2011
T. et al. JAMA; published online June 15, 2011;
Contact: Myles Wolf, University of Miami, Miami, Fla.
O.M. et al. N. Engl. J. Med. 359, 584-592 (2008)
G. et al. Nephrol. Dial. Transplant. 24, 2792-2796 (2009)
AND INSTITUTIONS MENTIONED
The Children's Hospital of Philadelphia, Philadelphia, Pa.
The Johns Hopkins University School of
Medicine, Baltimore, Md.
Kaiser Permanente, Oakland, Calif.
National Institutes of Health, Bethesda, Md.
Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, Pa.
Reata Pharmaceuticals Inc., Irving, Texas
St. John's Health System, Detroit, Mich.
Tulane University School of Public Health
and Tropical Medicine, New Orleans, La.
The University of Alabama at Birmingham, Birmingham, Ala.
University of California, San Francisco, Calif.
University of Illinois at Chicago, Chicago, Ill.
University of Miami Miller School of
Medicine, Miami, Fla.
University of Michigan Health System, Ann Arbor, Mich.
Vitae Pharmaceuticals Inc., Fort Washington, Pa.
Wayne State University School of Medicine, Detroit, Mich.